BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Novavax

Each vaccine stock is moving lower for a different reason.

Why BioNTech, Moderna, and Novavax Stocks Are Sinking Today

Pfizer

A fourth dose of the COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) provided significant protection against severe disease, hospitalization, and death for at least a month in older individuals. The study was conducted in Israel, when the Omicron.

Pfizer/BioNTech Fourth COVID-19 Vaccine Dose Protects Against Omicron For At Least One Month

Pfizer Inc. PFE, -0.02% and German partner BioNTech SE BNTX, +6.06% said Thursday a Phase 2/3 trial of their COVID-19 vaccine booster showed a high immune response in children aged 5-to-11-years old. Data from a sub-analysis of 30 sera from the trial showed a 36-fold increase in neutralizing titers against the omicron variant, which has become dominant globally.

Pfizer and BioNTech say data shows high immune response for COVID booster in children aged 5 to 11

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. These data demonstrate an increase in SARS-CoV-2 Omicron variant and wild-type strain neutralizing titers following a booster dose of the Pfizer-BioNTech COVID-1

Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.

Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines

Eli Lilly

Veru

Zynex Inc

Here are 4 top health care stocks to watch in the stock market today.

Best Health Care Stocks To Buy Right Now? 4 For Your List

An mRNA vaccine can potentially boost cell treatments used to fight blood cancer and make them more effective in solid tumors, BioNTech said, citing early data.

mRNA Cancer Treatment: Covid Vaccine Giant BioNTech Touts Promising Early Data

Matinas BioPharma Hlds

BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology.  The companies will collaborate on.

Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech

Before the Covid-19 pandemic, much of the focus of biotech companies working on mRNA technology was on applications in cancer.

Data From mRNA Cancer Treatment Look Positive, but Very Early

MAINZ, Germany and BEDMINSTER, New Jersey (USA), April 11, 2022 – BioNTech SE  (Nasdaq: BNTX, “BioNTech”) and Matinas BioPharma (NYSE AMER: MTNB, “Matinas”), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today that they have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology. The parties will closely collaborate on formulation, optimization, and in vitro testing.

BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines

MAINZ, Germany, April 11, 2022 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) presented data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and preliminary efficacy of the Company's novel CAR-T cell therapy candidate, BNT211, in patients with advanced solid tumors. The preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of BNT211. The data were presented in the Clinical Trials Plenary Session at the AACR Annual Meeting 2022 by Prof. John Haanen, M.D., Ph.D., Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.

BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR

MAINZ, Germany , April 8 , 2022 — BioNTech SE (Nasdaq: BNTX) today announced that it is one of the companies in Germany to be granted a pandemic preparedness contract by the Federal Republic of Germany. The framework agreement is aimed at pandemic preparedness including manufacturing and supply of mRNA vaccines in emergency situations in Germany.

BioNTech Granted Pandemic Preparedness Contract by German Federal Ministry of Health

I estimate BioNTech is worth $265 per share, implying a 57% upside potential. BioNTech and Pfizer signed orders to deliver 2.4 billion COVID-19 vaccine doses in 2022. I predict there will be more orders in the next nine months.

BioNTech: Buy The Dip

The European health agencies agreed that the fourth dose of mRNA-based COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) may be given to adults 80 years and above.

EU Agencies Doubtful About Need for 2nd COVID Booster

An Israel-based study has found that a fourth dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) vaccine lowered rates of COVID-19 infection among the elderly. However, the protection against disease appeared to be short-lived.

Pfizer/BioNTech's Second COVID-19 Vaccine Booster Provides Short-Lived Protection In Elderly, Israel Study Shows

Abbott Labs

AstraZeneca

UnitedHealth Group

Valneva SE

Are these health care stocks on your watchlist right now?

5 Top Health Care Stocks To Watch In The Stock Market Today

Axsome Therapeutics

Johnson & Johnson

Could these health care stocks be healthy additions to your portfolio?

3 Top Health Care Stocks To Watch Today

MAINZ, Germany, March 31, 2022 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a share repurchase program (the “Program”), pursuant to which the Company may purchase American depositary shares (ADSs) in the amount of up to $1.5 billion over the next two years. BioNTech expects to use all or a portion of the ADSs to satisfy upcoming settlement obligations under the Company's share-based payment arrangements.

BioNTech Announces ADS Repurchase Program

BioNTech (BNTX) stock is rising higher on Wednesday with the release of the biotechnology company's most recent earnings report. The post BioNTech News: Why Is BNTX Stock Up Today?

BioNTech News: Why Is BNTX Stock Up Today?

BioNTech SE (BNTX) CEO Ugur Sahin on Q4 2021 Results - Earnings Call Transcript

BioNTech SE shares (NASDAQ: BNTX) opened 8% up on Wednesday after the pharmaceutical company handily beat Street expectations for Q4 earnings and revenue. Notable figures in BioNTech Q4 earnings report Net profit printed at €3.17 billion ($3.51 billion), compared to last year's €3.66 million.

BioNTech reports unbelievable YoY growth for its fiscal Q4

BioNTech SE (NASDAQ: BNTX) reported Q4 FY21 revenues of €5.53 billion compared to €345.4 million a year ago, mainly due to high demand for the company's COVID-19 vaccine. BioNTech and its partner Pfizer Inc (NYSE: PFE) delivered approximately 2.6 billion.

Why BioNTech Shares Are Surging Today

German pharmaceutical company BioNTech SE reported soaring earnings and revenue for the fourth quarter, driven by the Covid-19 vaccine it produces with Pfizer Inc, and said it is starting a share buyback program of up to $1.5 billion over the next two years.

Dow Jones Newswires: BioNTech reports soaring earnings, revenue on COVID vaccine, plans $1.5 billion in buybacks

BioNTech says it plans to buy back up to $1.5 billion of stock over the next two years. It also will propose to pay a special dividend of €2 a share.

BioNTech's Earnings Top Estimates. It Plans a Buyback and Special Dividend.

Conference call and webcast scheduled for March 30, 2022 at 8:00 am ET (2:00 pm CET)

News for BioNTech SE Stock (BNTX)